Clinical data including FEV1 %predicted, body mass index (BMI), sweat chloride test, modified shuttle walk test, number of intravenous/oral antibiotics and hospitalisations were collected before LUMA–IVA therapy and then at 3 months and 12 months after LUMA–IVA. Spirometry was performed according to ERS/ATS guidelines using a regularly calibrated CareFusion MicroLab spirometer.15 (link) A sweat chloride test was performed using a Macroduct system by manufacturer’s guidelines. A modified shuttle walk test was performed at each visit. The number of courses of intravenous antibiotic for pulmonary exacerbations were recorded prospectively for 12 months after initiation of LUMA–IVA and compared with the number of courses of intravenous antibiotics 12 months before commencing LUMA–IVA.
Carefusion microlab spirometer
Manufactured by BD
The CareFusion MicroLab spirometer is a medical device used for measuring lung function. It provides measurements of various lung volume and airflow parameters to assist healthcare professionals in the assessment and monitoring of respiratory health.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using carefusion microlab spirometer
1
Clinical Outcomes with LUMA-IVA Therapy
2
Age-Related Respiratory Function Decline
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The respiratory system undergoes various anatomical, physiological and immunological changes with age. Ageing is associated with a progressive decline in respiratory function that accompanies changes in the structure of the chest wall due to loss of supporting tissue, increased air trapping and decreased respiratory muscle strength [28 ]. Respiratory function was measured using the CareFusion Microlab Spirometer with the participant seated. Measurements included forced expiratory volume in one second (FEV1, l), forced vital capacity (FVC, l) and forced expiratory flow (FEF) 25–75%. Measures of lung function (FEV1 and FVC) are associated with all-cause and cardiovascular mortality [29 , 30 ]. Low FEV1 is also recognised as an independent predictor of non-cardiopulmonary comorbidities including diabetes, chronic kidney disease, osteoporosis and dementia [31 –34 ]. For the purposes of this manuscript the highest FEV1 and FVC reading was used. A maximum of five attempts were undertaken to obtain three satisfactory readings. Analyses are only based on participants who obtained at least three satisfactory readings.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!